Skip to main content
SpringerLink
Log in

Activity of GH/IGF-1 axis in burn patients: Comparison with normal subjects and patients with GH deficiency

  • Original Article
  • Published:
Journal of Endocrinological Investigation Aims and scope Submit manuscript

Abstract

The aim of this study was to clarify the activity of GH/IGF-I axis as well as the variations of nutritional parameters following a thermal injury in man. To this goal, in 22 patients with burn [BURN, age (mean±SE): 46.5±3.4 yr, BMI: 25.0±0.8 kg/m2, % burn surface area: 26.0±3.0%, ROI score: 0.22± 0.1] we evaluated IGF-I, IGF binding protein (IGFBP- 3), GH, GH binding protein (GHBP), pre-albumin (pre-A), albumin (A) and transferrin (TRA) levels on days 1, 3, 7, 14 and 28 after intensive care unit (ICU) admission. IGF-I, IGFBP-3, GH and GHBP levels were also assayed basally in 29 normal subjects (Ns) (Ns, age: 47.5±2.8 yr, BMI: 22.0±1.4 kg/m2) and in 34 panhypopituitary patients with severe GH deficiency (GHD, age: 42.7±2.5 yr, BMI: 25.6±0.8 kg/m2). On ICU day 1, IGF-I and IGFBP-3 in BURN were higher than those in GHD (p<0.05 for both, respectively) and lower than those in Ns (p<0.05) while GH levels in BURN did not differ from those in Ns and higher than GHD (p<0.01). In BURN, IGF-I and IGFBP-3 levels showed a progressive decline (p<0.05) with nadir on day 14, when they overlapped those in GHD, and then an increase on day 28, though persisting lower than in Ns, while GH levels did not vary during ICU stay. IGF-I levels were associated neither to burn extension nor to ROI score. On ICU day 1 pre-A, A and TRA levels were similar to those in Ns, but underwent a progressive decrease with nadir on day 7 (p<0.001) for pre-A and TRA, and later, on day 14 (p<0.05) for A; pre-A and TRA but not A showed a rebound increase (p<0.01) on day 14, though persistingly lower than in Ns. In conclusion, our present data firstly show the time course variation of IGF-I levels in burn patients as function of nutritional and hormonal variables. It has to be emphasized that in the most critical phase after burn injuries, IGF-I levels are as low as in hypopituitary patients with severe GHD. The physiological basis which leads to the impairment of this endogenous anabolic drive in this phase is, however, not clear yet.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Jenkins R.C., Ross R.J.M. The endocrinology of the critically ill. Curr. Opin. Endocrinol. Diab. 1996, 3: 138–145.

    Article  Google Scholar 

  2. Van den Berghe G., de Zegher F. Anterior pituitary function during critical illness and dopamine treatment. Crit. Care Med. 1996, 41: 1580–1588.

    Article  Google Scholar 

  3. Faber J., Kirkegaard C., Rasmussen B., et al. Pituitary-thyroid axis in critical illness. J. Clin. Endocrinol. Metab. 1987, 65: 315–320.

    Article  CAS  PubMed  Google Scholar 

  4. Ross R.J.M., Chew S.L. Acquired growth hormone resistance. Eur. J. Endocrinol. 1995, 132: 655–660.

    Article  CAS  PubMed  Google Scholar 

  5. Van den Berghe G., de Zegher F., Lauwers P. Growth hormone secretion in critical illness: effects of dopamine. J. Clin. Endocrinol. Metab. 1994, 79: 1141–1146.

    PubMed  Google Scholar 

  6. Ross R., Miell J., Freeman E., et al. Critically ill patients have high basal growth hormone levels with attenuated oscillatory activity associated with low levels of insulinlike growth factor-I. Clin. Endocrinol. (Oxf.) 1991, 35: 47–54.

    Article  CAS  Google Scholar 

  7. Cotterill A.M., Mendel P., Holly J.M., et al. The differential regulation of the circulating levels of the insulin-like growth factors and their binding protein (IGFBP) 1, 2 and 3 after elective abdominal surgery. Clin. Endocrinol. (Oxf.) 1996, 44: 91–101.

    Article  CAS  Google Scholar 

  8. Timmins A.C., Cotterill A.M., Hughes S.C., et al. Critical illness is associated with low circulating concentrations of insulin-like growth factors-I and II, alterations in insulin-like binding-proteins, and induction of an insulin-like growth factor binding protein 3 protease. Crit. Care Med. 1996, 24: 1460–1466.

    Article  CAS  PubMed  Google Scholar 

  9. Jeevanandan M., Holaday N.J., Petersen S.R. Plasma levels of insulin-like growth factor binding protein-3 in acute trauma patients. Metabolism 1995, 44: 1205–1208.

    Article  Google Scholar 

  10. Thissen J.P., Keteslegers J.M., Underwood L.E. Nutritional regulation of insulin-like growth factors. Endocr. Rev. 1994, 15: 80–85.

    CAS  PubMed  Google Scholar 

  11. Phillips L.S., Unterman T.G. Somatomedin activity in disorders of nutrition and metabolism. J. Clin. Endocrinol. Metab. 1995, 13: 145–180.

    Article  Google Scholar 

  12. Ross R.J.M., Miell J.P., Holly J.M., et al. Levels of GH binding activity, IGFBP-1, insulin, blood glucose and cortisol in intensive care patients. Clin. Endocrinol. 1991, 35: 361–367.

    Article  CAS  Google Scholar 

  13. Nygren J., Sammann M., Malm M., et al. Distributed anabolic hormonal patterns in burned patients: the relation to glucagon. Clin. Endocrinol. (Oxf.) 1995, 43: 491–500.

    Article  CAS  Google Scholar 

  14. Herndon D.N., Barrow R.E., Kunkel K.R., Broemeling L., Rutan R.L. Effects of recombinant human growth hormone on donor site healing in severely burned children. Ann. Surg. 1990, 212: 424–431.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  15. Ziegler T.R., Rombeau J.L., Young L.S., et al. Recombinant human growth hormone enhances the metabolic efficacy of parenteral nutrition: a double-blind, randomized controlled study. J. Clin. Endocrinol. Metab. 1992, 74: 865–873.

    Article  CAS  PubMed  Google Scholar 

  16. Voerman H.J., van Schijndel R.J., Groeneveld A.B., et al. Effects of recombinant human growth hormone in patients with severe sepsis. Ann. Surg. 1992, 216: 648–651.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  17. Declan Fleming R.Y., Rutan R.L., Jahoor F., et al. Effect of recombinant human growth hormone on catabolic hormones and free fatty acids following thermal injury. J. Trauma 1992, 32: 698–703.

    Article  Google Scholar 

  18. Vara-Thorbeck R., Ruiz-Requena R., Guerrero J.A. Effects of human growth hormone on the catabolic state after surgical trauma. Horm. Res. 1996, 45: 55–60.

    Article  CAS  PubMed  Google Scholar 

  19. Takala J., Ruokonen E., Webster N.R., et al. Increased mortality associated with growth hormone treatment in critically ill adults. N. Engl. J. Med. 1999, 341: 785–792.

    Article  CAS  PubMed  Google Scholar 

  20. Belcher H.J.C.R., Mercer D., Judkins K.C. Biosynthetic human growth hormone in burned patients: a pilot study. Burns 1989, 15: 99–107.

    Article  CAS  PubMed  Google Scholar 

  21. Frost R.A., Fuhrer J., Steigbigel R., et al. Wasting in the acquired immune deficiency syndrome is associated with multiple defects in the serum insulin-like growth factor system. Clin. Endocrinol. (Oxf.) 1996, 44: 501–514.

    Article  CAS  Google Scholar 

  22. Jeffries M.K., Lee Vance M. Growth hormone and cortisol secretion in patients with burn injury. J. Burn Care Rehabil. 1992, 13: 391–395.

    Article  CAS  PubMed  Google Scholar 

  23. Melarvie S., Jeevanandam M., Holaday N.J., Petersen S.R. Pulsatile nature of growth hormone levels in critical ill trauma victims. Surgery 1995, 117: 402–408.

    Article  CAS  PubMed  Google Scholar 

  24. Heijlinberg R., Sauerwein H.P., Brabant G., et al. Circadian growth hormone secretion in asymptomatic human immune deficiency virus infection and acquired immunodeficiency syndrome. J. Clin. Endocrinol. Metab. 1996, 81: 4028–4032.

    Google Scholar 

  25. Gianotti L., Broglio F., Aimaretti G., et al. Low IGF-I levels are often uncoupled with elevated GH levels in catabolic conditions. J. Endocrinol. Invest. 1998, 21: 115–121.

    Article  CAS  PubMed  Google Scholar 

  26. Casanueva F.F. Physiology of growth hormone secretion and action. Endocrinol. Metab. Clin. North Am. 1992, 21: 483–517.

    CAS  PubMed  Google Scholar 

  27. Frohman L.A., Jansson J.O. Growth hormone releasing hormone. Endocr. Rev. 1986, 3: 223–231.

    Article  Google Scholar 

  28. Ghigo E., Arvat E., Muccioli G., Camanni F. Growth hormonereleasing peptides. Eur. J. Endocrinol. 1997, 136: 445–460.

    Article  CAS  PubMed  Google Scholar 

  29. Smith R.G., Van der Ploeg L.H.T., Howard A.D., et al. Peptidomimetic regulation of growth hormone secretion. Endocr. Rev. 1997, 18: 621–645.

    Article  CAS  PubMed  Google Scholar 

  30. Van den Berghe G., de Zegher F., Veldhuis J.D., et al. The somatotropic axis in critical illness: effect of continuous growth hormone (GH)-releasing hormone and GH-releasing peptide-2 infusion. J. Clin. Endocrinol. Metab. 1997, 82: 590–599.

    PubMed  Google Scholar 

  31. Abribat T., Brazeau P., Davignon I., Garrel D.R. Insulin-like growth factor-I blood levels in severely burned patients: effects of time post injury, age of patient and severity of burn. Clin. Endocrinol. (Oxf.) 1993, 39: 583–589.

    Article  CAS  Google Scholar 

  32. Bereket A., Wilson T.A., Blethen S.L., et al. Regulation of the acid-labile subunit of the insulin-like growth factor ternary complex in patients with insulin-dependent diabetes mellitus and severe burns. Clin. Endocrinol. (Oxf.) 1996, 44: 525–532.

    Article  CAS  Google Scholar 

  33. Voerman H.J., Groeneveld A.B., de Boer H., et al. Time course and variability of the endocrine and metabolic response to severe sepsis. Surgery 1993, 114: 951–959.

    CAS  PubMed  Google Scholar 

  34. Roi L.D., Flora J.D., Davis T.M., Wolfe R.A. Two new burn severity indices. J. Trauma 1983, 23: 1023–1030.

    Article  CAS  PubMed  Google Scholar 

  35. Baumann G., Stolar M.W., Amburn K., et al. A specific growth hormone-binding protein in human plasma: initial characterization. J. Clin. Endocrinol. Metab. 1986, 62: 134–141

    Article  CAS  PubMed  Google Scholar 

  36. Donaghy A.J., Baxter R.C. Insulin-like growth factor bioactivity and its modification in growth hormone resistant states. In: Ross R.J.M., Savage M.O. (Eds.), Growth hormone resistance. Bailleire’s Tindall Clin. End. Metab., W.B. Saunders, London, 1996, p. 421.

    Google Scholar 

  37. Belcher H.J.C.R., Mercer D., Judkins K.C. Biosynthetic human growth hormone in burned patients: a pilot study. Burns 1989, 15: 99–107.

    Article  CAS  PubMed  Google Scholar 

  38. Frayn K.N. Hormonal control of metabolism in trauma and sepsis. Clin. Endocrinol. (Oxf.) 1986, 24: 577–599.

    Article  CAS  Google Scholar 

  39. Dahn M.S., Lange M.P., Jacobs L.A. Insulin-like growth factor- I production is inhibited in human sepsis. Arch. Surg. 1988, 123: 1409–1414.

    Article  CAS  PubMed  Google Scholar 

  40. Imura H., Fukata J., Mori T. Cytokines and endocrine function: an interaction between the immune and neuroendocrine systems. Clin. Endocrinol. (Oxf.) 1991, 35: 107–115.

    Article  CAS  Google Scholar 

  41. Jones J.I., Clemmons D.R. Insulin-like growth factors and their binding proteins: biological actions. Endocr. Rev. 1995, 16: 3–34.

    CAS  PubMed  Google Scholar 

  42. De Boer H., Block G.J., Poo-Snijders C., Van der Venn E.A. Diagnosis of growth hormone deficiency in adults. Lancet 1994, 343: 1645–1646.

    Article  PubMed  Google Scholar 

  43. Ghigo E., Aimaretti G., Gianotti L., et al. New approach to the diagnosis of growth hormone deficiency in adults. Eur. J. Endocrinol. 1996, 134: 352–356.

    Article  CAS  PubMed  Google Scholar 

  44. Clemmons D.R., Seek M., Underwood L.E. Supplementary essential amino acids augment the somatomedin-C/insulinlike growth factor-I response to refeeding after fasting. Metabolism 1985, 34: 391–395.

    Article  CAS  PubMed  Google Scholar 

  45. Baumann G., Shaw M.A., Amburn K. Circulating growth hormone binding proteins. J. Endocrinol. Invest. 1994, 17: 67–81.

    Article  CAS  PubMed  Google Scholar 

  46. Golden M.H.N. Transport proteins as indices of protein status. Am. J. Clin. Nutr. 1982, 35: 1159–1165.

    CAS  PubMed  Google Scholar 

  47. Ingenbleek Y., De Visscher M., De Nayer P. Measurement of prealbumin as index of protein-calorie malnutrition. Lancet 1972, 2: 106–108.

    Article  CAS  PubMed  Google Scholar 

  48. Bollero D., Gianotti L., Stella M., et al. Variations in nutritional parameters after thermal injury in man. Ann. Burns Fire Dis. 1998, 11: 100–104.

    Google Scholar 

  49. Veldhuis J.D. New modalities for understanding dynamic regulation of the somatotropic (GH) axis: explication of gender differences in GH neuroregulation in the human. J. Ped. Endocrinol. Metab. 1996, 9: 237–253.

    Google Scholar 

  50. De Feo P.P. Hormonal regulation of human protein metabolism. Eur. J. Endocrinol. 1996, 135: 7–18.

    Article  PubMed  Google Scholar 

  51. Wolf S.E., Barrow R.E., Herndon D.N. Growth hormone and IGF-I therapy in the hypercatabolic patient. In: Ross R.J.M., Savage M.O. (Eds.), Growth hormone resistance. Baillieres Tindall Clin. End. Metab., W.B. Saunders, London, 1996, p. 447.

    Google Scholar 

  52. Froesch E.R., Zenobi P.D., Hussain M. Metabolic and therapeutic effects of insulin-like growth factor-I. Horm. Res. 1994, 42: 66–71.

    Article  CAS  PubMed  Google Scholar 

  53. Marin P., Kvist H., Lindstedt G., Sjostrom L., Bjorntorp P. Low concentrations of insulin-like growth factor-I in abdominal obesity. Int. J. Ob. Rel. Metab. Dis. 1993, 17: 83–89.

    CAS  Google Scholar 

  54. Pasquali R., Cantobelli S., Casimirri F., et al. The hypothalamic- pituitary-adrenal axis in obese women with different patterns of body fat distribution. J. Clin. Endocrinol. Metab. 1993, 77: 341–346.

    CAS  PubMed  Google Scholar 

  55. Kerrigan J.R., Rogol A.D. The impact of gonadal steroid hormone action on growth hormone secretion during childhood and adolescence. Endocr. Rev. 1992, 13: 281–298.

    CAS  PubMed  Google Scholar 

  56. Weissberger A.J., Ho K.K.Y., Lazarus L. Contrasting effects of oral and transdermal routes of estrogen replacement therapy on 24-hour growth hormone (GH) secretion, insulin- like growth factor-I, and GH-binding protein in postmeno- pausal women. J. Clin. Endocrinol. Metab. 1991, 72: 374–381.

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Divisione di Endocrinologia, Dipartimento di Medicina Interna, Università di Torino, C.so Dogliotti 14, 10126, Torino, Italy

    L. Gianotti, F. Broglio, F. Lanfranco, G. Aimaretti, S. Destefanis &  Ezio Ghigo

  2. Division of Plastic Surgery, Burn Unit, CTO Hospital, Turin, Italy

    M. Stella, D. Bollero & G. Magliacani

  3. Pharmacia & Upjohn, Metabolic Diseases, Milan, Italy

    M. Casati

Authors
  1. L. Gianotti
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. M. Stella
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. D. Bollero
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. F. Broglio
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. F. Lanfranco
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. G. Aimaretti
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. S. Destefanis
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. M. Casati
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. G. Magliacani
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Ezio Ghigo
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Ezio Ghigo.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Gianotti, L., Stella, M., Bollero, D. et al. Activity of GH/IGF-1 axis in burn patients: Comparison with normal subjects and patients with GH deficiency. J Endocrinol Invest 25, 116–124 (2002). https://doi.org/10.1007/BF03343974

Download citation

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF03343974

Key-words

Search

Navigation